Skip to content

Study · Observational study · n = 200 · 2025

5 results

Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States.

Hankosky ER, Desai K, Chinthammit C, Grabner M, Stockbower G, He X, Mojdami D, Wenziger C, Gibble TH

Diabetes & metabolism7 Mar 2025Cited by 11 (Europe PMC)

PMID40057019 (opens in a new tab)DOI10.1016/j.diabet.2025.101636 (opens in a new tab)PepBankPUB-40057019
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In US adults without type 2 diabetes who persisted on tirzepatide for 6 months and were GLP-1 receptor agonist naive, mean weight fell by 12.9%.

    In plain wordsIn US adults without type 2 diabetes who stayed on tirzepatide for 6 months, average weight fell by about 13%.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMean weight reduction at 6 months
    Study

    n = 200

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Mean weight reduction
    12.9%
    Persistent+GLP-1 naive cohort

    Source sentences

    Summary
    Individuals in the Persistent+GLP-1 naive cohort with pre- and post-index weight and BMI measurements (n = 200) achieved mean weight reduction of 12.9 % at 6-months post-index (≥ 5 %: 88.5 %; ≥ 10 %: 69.0 %).
    2 context sentences
    Summary · context
    Tirzepatide effectiveness was assessed among individuals who were OMM-eligible, naive to glucagon-like peptide-1 receptor agonists, and persistent on tirzepatide for ≥6 months (Persistent+GLP-1 naive cohort).
    Summary · context
    Key eligibility criteria were: age ≥ 18 years; ≥ 1 tirzepatide claim; no T2D diagnosis codes or glycated hemoglobin ≥ 6.5 %, no anti-diabetes medications (except metformin); and continuous medical/pharmacy enrollment for ≥ 12 months pre-index (Overall cohort).
  2. 02HumanObservational studyEfficacy outcome

    In US adults without type 2 diabetes who persisted on tirzepatide for 6 months, 88.5% lost at least 5% of weight.

    In plain wordsIn US adults without type 2 diabetes who stayed on tirzepatide for 6 months, most lost at least 5% of their weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProportion with at least 5% weight reduction at 6 months
    Study

    n = 200

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Weight reduction of at least 5%
    88.5%
    Persistent+GLP-1 naive cohort

    Source sentences

    Summary
    Individuals in the Persistent+GLP-1 naive cohort with pre- and post-index weight and BMI measurements (n = 200) achieved mean weight reduction of 12.9 % at 6-months post-index (≥ 5 %: 88.5 %; ≥ 10 %: 69.0 %).
    2 context sentences
    Summary · context
    Tirzepatide effectiveness was assessed among individuals who were OMM-eligible, naive to glucagon-like peptide-1 receptor agonists, and persistent on tirzepatide for ≥6 months (Persistent+GLP-1 naive cohort).
    Summary · context
    Key eligibility criteria were: age ≥ 18 years; ≥ 1 tirzepatide claim; no T2D diagnosis codes or glycated hemoglobin ≥ 6.5 %, no anti-diabetes medications (except metformin); and continuous medical/pharmacy enrollment for ≥ 12 months pre-index (Overall cohort).
  3. 03HumanObservational studyEfficacy outcome

    In US adults without type 2 diabetes who persisted on tirzepatide for 6 months, 69.0% lost at least 10% of weight.

    In plain wordsIn US adults without type 2 diabetes who stayed on tirzepatide for 6 months, 69.0% lost at least 10% of their weight.

    Peptide
    Tirzepatide
    Outcome
    IncreaseProportion with at least 10% weight reduction at 6 months
    Study

    n = 200

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Weight reduction of at least 10%
    69%
    Persistent+GLP-1 naive cohort

    Source sentences

    Summary
    Individuals in the Persistent+GLP-1 naive cohort with pre- and post-index weight and BMI measurements (n = 200) achieved mean weight reduction of 12.9 % at 6-months post-index (≥ 5 %: 88.5 %; ≥ 10 %: 69.0 %).
    2 context sentences
    Summary · context
    Tirzepatide effectiveness was assessed among individuals who were OMM-eligible, naive to glucagon-like peptide-1 receptor agonists, and persistent on tirzepatide for ≥6 months (Persistent+GLP-1 naive cohort).
    Summary · context
    Key eligibility criteria were: age ≥ 18 years; ≥ 1 tirzepatide claim; no T2D diagnosis codes or glycated hemoglobin ≥ 6.5 %, no anti-diabetes medications (except metformin); and continuous medical/pharmacy enrollment for ≥ 12 months pre-index (Overall cohort).
  4. 04HumanObservational studyOther

    In US adults without type 2 diabetes who were eligible for obesity management medication, 73.8% were persistent on tirzepatide.

    In plain wordsIn US adults without type 2 diabetes, 73.8% of those eligible for obesity treatment stayed on tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableTirzepatide persistence
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Persistence
    73.8%
    OMM-eligible cohort

    Source sentences

    Summary
    Persistence in the OMM-eligible cohort was 73.8 %
    2 context sentences
    Summary · context
    Tirzepatide persistence and utilization (6-months post-index) were assessed among obesity management medication (OMM)-eligible individuals (body mass index [BMI] ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity-related complication [ORC]; OMM-eligible cohort).
    Summary · context
    Key eligibility criteria were: age ≥ 18 years; ≥ 1 tirzepatide claim; no T2D diagnosis codes or glycated hemoglobin ≥ 6.5 %, no anti-diabetes medications (except metformin); and continuous medical/pharmacy enrollment for ≥ 12 months pre-index (Overall cohort).
  5. 05HumanObservational studyOther

    In US adults without type 2 diabetes, 56.2% were receiving less than 10 mg tirzepatide by the sixth prescription fill.

    In plain wordsIn US adults without type 2 diabetes, over half were still on tirzepatide doses below 10 mg by the sixth fill.

    Peptide
    Tirzepatide
    Outcome
    Not applicableTirzepatide dose at sixth prescription fill
    Study

    n: not reported in source

    Outcome group
    Treatment adherence and retention · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Proportion receiving under 10 mg
    56.2%
    by the sixth prescription fill

    Source sentences

    Summary
    by the sixth prescription fill, 56.2 % were receiving < 10 mg tirzepatide.
    2 context sentences
    Summary · context
    Tirzepatide persistence and utilization (6-months post-index) were assessed among obesity management medication (OMM)-eligible individuals (body mass index [BMI] ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity-related complication [ORC]; OMM-eligible cohort).
    Summary · context
    Key eligibility criteria were: age ≥ 18 years; ≥ 1 tirzepatide claim; no T2D diagnosis codes or glycated hemoglobin ≥ 6.5 %, no anti-diabetes medications (except metformin); and continuous medical/pharmacy enrollment for ≥ 12 months pre-index (Overall cohort).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.